Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01114269 · ClinicalTrials.gov registry record

PRE-DETERMINE Cohort Study

A clinical trial of Coronary Artery Disease and Sudden Cardiac Death, sponsored by Brigham and Women's Hospital.

Active
Registry status
5,764
Enrollment target
20
Study locations

NCT01114269: Active study of Coronary Artery Disease and Sudden Cardiac Death, sponsored by Brigham and Women's Hospital.

NCT01114269 is a study of Coronary Artery Disease and Sudden Cardiac Death that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 5,764 participants, above the 1,261-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (357% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01114269, a study of Coronary Artery Disease and Sudden Cardiac Death, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
5,764 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to determine whether biologic markers and ECGs can be utilized to advance SCD risk prediction in patients with CHD and LVEF\>30-35%. The overarching goal of the study is to identify a series of markers that alone or in combination specifically predict risk of arrhythmic death as compared to other causes of mortality among this at risk population of coronary heart disease (CHD) patients with preserved left ventricular ejection fraction (LVEF\> 30-35%). If biologic or ECG markers are identified that can specifically predict risk of ventricular arrhythmias, then these markers may serve as relatively inexpensive methods to identify those at risk. The public health impact of identifying markers could be quite substantial, leading to more efficient utilization of ICDs and advances in our understanding of mechanisms underlying SCD.

Primary Outcome

A definite sudden cardiac death (SCD) is defined as a death or fatal cardiac arrest occurring within 1 hour of symptom onset or the presence of autopsy consistent with SCD (e.g. acute coronary thrombosis). Probable SCD is defined as an unwitnessed death or death during sleep where the participant was observed to be symptom-free within the preceding 24 hours. Arrhythmic death is defined as the abrupt spontaneous collapse of circulation without antecedent circulatory or neurologic impairment. Deat

Study Locations (20)

Florida

  • Bay Area Cardiology Associates, P.A. - Brandon
  • University of Florida - Gainsville - Gainesville
  • Reliable Clinical Research - Miami
  • Mount Sinai Medical Center - Miami Beach
  • Florida Hospital - Orlando
  • Orlando Regional Medical Center - Orlando
  • Palm Beach Gardens Research Center - Palm Beach Gardens
  • Velella Research - Sarasota
  • Tallahassee Research Institute, Inc. - Tallahassee
  • Cardiology Associates of Palm Beach - West Palm Beach - West Palm Beach

Arizona

  • Phoenix Heart, PLLC - Glendale
  • Cardiovascular Consultants - Phoenix

Colorado

  • Memorial Health System - Colorado Springs
  • Colorado Heart and Vascular - Denver

Georgia

  • Georgia Heart Specialist - Covington
  • Northeast Georgia Heart Center, P.C. - Gainesville

Illinois

  • University of Chicago - Chicago
  • Advocate Medical Group - Chicago

Alaska

  • Alaska Heart Institute - Anchorage

California

  • Beaver Medical Group/Clinical Care Research - Banning

Trial Details

FieldValue
Enrollment Target 5,764 participants
Start Date 2007-07
Est. Completion 2026-11
Brigham and Women's Hospital

937 total trials

What the registry record for NCT01114269 still lists

NCT01114269 is an observational study that tracks outcomes without assigning an intervention. Its 5,764 participants enrollment target places it among the larger protocols in the corpus, above the 1,261-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (357% higher).

The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01114269 names 20 study sites across 7 states, led by Florida, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT01114269 about?

NCT01114269 is a clinical study titled "PRE-DETERMINE Cohort Study". This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to determine whether biol...

What is the current status of trial NCT01114269?

This trial is currently active not recruiting. The enrollment target is 5,764 participants. The study started on 2007-07. Estimated completion is 2026-11.

What conditions does trial NCT01114269 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Sudden Cardiac Death, Left Ventricular Dysfunction.

Who is sponsoring clinical trial NCT01114269?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01114269 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01114269's enrollment target sits among peer trials

5,764 9th of 219 higher than 211 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04983875 · 5,708 participants · NA

    Mammography and Breast Arterial Calcification: An Information-Sharing Trial

  • NCT06627335 · 5,621 participants

    An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

  • NCT05636176 · 5,600 participants · Phase 3

    A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

  • NCT06981598 · 5,586 participants · NA

    Prevention of Psychological Health Problems Via Integrated Operational Support

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01114269, the US trial registry maintained by the National Library of Medicine. NCT01114269 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.